Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2018 09:00 ET | Source: Altimmune, Inc.

Altimmune Announces $4.9 million Registered Direct Offering of Common Stock

GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into purchase agreements with several...
September 24, 2018 08:00 ET | Source: Altimmune, Inc.

Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield™ Development

New funding will allow examination of mucosal immune response and additional vaccine characterization GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a...
September 04, 2018 08:00 ET | Source: Altimmune, Inc.

Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine

Six-month data demonstrates: A statistically superior mucosal immune response providing a first line of defense against infection;A durable serum immune response at six months compared to over 50%...
August 31, 2018 08:00 ET | Source: Altimmune, Inc.

Altimmune Announces Initial Single-Dose Data from Its NasoShield Phase 1 Study

Studies funded by BARDA GAITHERSBURG, Md., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced initial data from its Phase...
August 14, 2018 16:01 ET | Source: Altimmune, Inc.

Altimmune Announces Second Quarter 2018 Financial Results and Provides Corporate Update

Conference call and webcast scheduled for tomorrow, August 15, 2018, at 8:30am ET GAITHERSBURG, Md., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage...
August 07, 2018 08:00 ET | Source: Altimmune, Inc.

Altimmune to Announce Second Quarter 2018 Financial Results on August 15

GAITHERSBURG, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the...
July 12, 2018 08:00 ET | Source: Altimmune, Inc.

Altimmune Restructures Financing Agreement with Majority of the Remaining Series B Investors

GAITHERSBURG, Md., July 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has...
July 10, 2018 08:00 ET | Source: Altimmune, Inc.

Altimmune Appoints Mitchel Sayare as Executive Chairman of the Board, and Adds José Ochoa to Its Leadership Team as Chief Business Officer

GAITHERSBURG, Md., July 10, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on infectious disease, today announced it has appointed Mitchel...
June 22, 2018 16:15 ET | Source: Altimmune, Inc.

Altimmune Restructures Financing Agreement

GAITHERSBURG, Md., June 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has...
May 15, 2018 16:01 ET | Source: Altimmune, Inc.

Altimmune Announces First Quarter 2018 Financial Results and Provides Corporate Update

Conference call and webcast scheduled for tomorrow, May 16 at 8:30am ET GAITHERSBURG, Md., May 15, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage...